Baseline demographics of patients undergoing eculizumab discontinuation
| . | N = 280 . |
|---|---|
| Age at time of eculizumab initiation | |
| Median (Q1-Q3) | 28 (14.25-41.0) |
| N/A | 54 |
| Sex, n (%) | |
| Male | 85 (40.1) |
| Female | 127 (59.9) |
| N/A | 68 |
| Prior TMA event∗ , n (%) | |
| Yes | 94 (79.7) |
| No | 24 (20.3) |
| N/A | 162 |
| Kidney status, n (%) | |
| Native | 201 (88.9) |
| Allograft | 25 (11.1) |
| N/A | 54 |
| Dialysis during CM-TMA event, n (%) | |
| Yes | 48 (55.8) |
| No | 38 (44.2) |
| N/A | 194 |
| Complement gene variant, n (%) | |
| Yes | 168 (60) |
| No variant | 112 (40) |
| Gene variant number† , n (%) | |
| Single variant | 148 (88.1) |
| >1 concomitant variant | 20 (11.9) |
| Single-gene variant type, n (%) | |
| CFH | 47 (31.8) |
| MCP/CD46 | 35 (23.6) |
| C3 | 11 (7.4) |
| CFI | 15 (10.1) |
| Time on eculizumab (mo) | |
| Median (Q1-Q3) | 8 (4.5-14.0) |
| N/A | 67 |
| Dialysis at eculizumab d/c, n (%) | |
| Yes | 12 (6) |
| No | 187 (94) |
| N/A | 81 |
| Follow up after eculizumab d/c (mo) | |
| Median (95% CI) | 23 (20-24) |
| N/A | 62 |
| . | N = 280 . |
|---|---|
| Age at time of eculizumab initiation | |
| Median (Q1-Q3) | 28 (14.25-41.0) |
| N/A | 54 |
| Sex, n (%) | |
| Male | 85 (40.1) |
| Female | 127 (59.9) |
| N/A | 68 |
| Prior TMA event∗ , n (%) | |
| Yes | 94 (79.7) |
| No | 24 (20.3) |
| N/A | 162 |
| Kidney status, n (%) | |
| Native | 201 (88.9) |
| Allograft | 25 (11.1) |
| N/A | 54 |
| Dialysis during CM-TMA event, n (%) | |
| Yes | 48 (55.8) |
| No | 38 (44.2) |
| N/A | 194 |
| Complement gene variant, n (%) | |
| Yes | 168 (60) |
| No variant | 112 (40) |
| Gene variant number† , n (%) | |
| Single variant | 148 (88.1) |
| >1 concomitant variant | 20 (11.9) |
| Single-gene variant type, n (%) | |
| CFH | 47 (31.8) |
| MCP/CD46 | 35 (23.6) |
| C3 | 11 (7.4) |
| CFI | 15 (10.1) |
| Time on eculizumab (mo) | |
| Median (Q1-Q3) | 8 (4.5-14.0) |
| N/A | 67 |
| Dialysis at eculizumab d/c, n (%) | |
| Yes | 12 (6) |
| No | 187 (94) |
| N/A | 81 |
| Follow up after eculizumab d/c (mo) | |
| Median (95% CI) | 23 (20-24) |
| N/A | 62 |
N/A, not available.
Prior TMA event: authors of original publication indicated that episodes for which eculizumab was started was not their first TMA episode; however, the episode described in the current cohort was the first TMA episode for which eculizumab had been used as therapy.
Patients with only likely benign or benign variants were not included in this count.